CHIR-98014 is a potent and selective human GSK-3 inhibitor for human GSK-3ɑ and human GSK-3β with IC50 of 0.65 and 0.58 nM, respectively. CHIR-98014 inhibits human GSK-3β with Ki values of 0.87 nM. Although CHIR-98014 serves as a simple competitive inhibitor of ATP binding, CHIR-98014 exhibits from 500-fold to <1000-fold selectivity for GSK-3 versus 20 other protein kinases including CDC2, erk2, tie2, KDR et al. CHIR-98014 prevents CDC2 with an IC50 of 3.7 μM.
|Source||Stem Cell Reports (2014). Figure 5. CHIR-98014|
|Cell Lines||Cortical and hippocampal primary neuronal cells|
|Incubation Time||12 h|
|Results||Using confocal microscopy, we demonstrated that treatment of the cortical aswell as hippocampal neuronswith 10 μMCHIR98014 prevents loss of neurites caused by 20 μMPrP1–30|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Related GSK-3 Products|
IM-12 is a potent and selective GSK-3β inhibitor with IC50 of 53 nM, which also enhances canonical Wnt signalling.
SB415286 is a potent GSK3α inhibitor with IC50/Ki of 78 nM/31 nM with equally effective inhibition of GSK-3β.
TDZD-8 is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC.
LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. Phase 1/2.
AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor, inhibits human GSK3α and GSK3β with Ki of 6.9 nM and 31 nM, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.